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Jung D-S, Li JJ, Kwak S-J, Lee SH, Park J, Song YS, Yoo T-H,
Han SH, Lee JE, Kim DK, Moon SJ, Kim YS, Han DS, Kang S-W.
FR167653 inhibits fibronectin expression and apoptosis in diabetic
glomeruli and in high-glucose-stimulated mesangial cells. Am J
Physiol Renal Physiol 295: F595–F604, 2008. First published June 4,
2008; doi:10.1152/ajprenal.00624.2007.—Previous in vitro studies
suggest that the p38 MAPK pathway may be involved in the patho-
genesis of diabetic nephropathy, but the consequences of the inhibi-
tion of the p38 MAPK pathway have not been well elucidated in
diabetic (DM) glomeruli. This study was undertaken to investigate the
effect of p38 MAPK inhibitor, FR167653, on fibronectin expression
and apoptosis in DM glomeruli and in high-glucose-stimulated mes-
angial cells (MC). In vivo, 32 Sprague-Dawley rats were injected with
diluent (control, N  16) or streptozotocin intraperitoneally (DM,
N  16). Eight rats from each group were treated with FR167653 for
3 mo. In vitro, rat MC were exposed to medium containing 5.6 mM
glucose or 30 mM glucose [high glucose (HG)] with or without 106
M FR167653 for 24 h. Fibronectin mRNA and protein expression
were determined by real-time PCR and Western blot, respectively.
Western blot for apoptosis-related molecules, terminal deoxynucleo-
tidyl transferase dUTP-mediated nick-end labeling assay, and Hoechst
33342 staining were performed to determine apoptosis. FR167653
ameliorated the increases in fibronectin-to-GAPDH mRNA ratio and
protein expression in DM glomeruli by 89 and 79% and in HG-
stimulated MC by 70 and 91%, respectively (P  0.05). Under
diabetic conditions, Bcl-2 protein expression was decreased, whereas
cleaved caspase-3 protein expression was increased (P  0.05), and
these changes were inhibited by FR167653 treatment. Apoptotic cells
were also significantly increased in DM glomeruli and in HG-stimu-
lated MC (P  0.05), and FR167653 ameliorated these increases in
apoptotic cells, both in vivo and in vitro. In conclusion, these findings
suggest that the inhibition of the p38 MAPK pathway has a beneficial
effect on the development of diabetic nephropathy by inhibiting the
increase in fibronectin expression and apoptosis.
p38 mitogen-activated protein kinase; fibrosis; apoptosis; diabetic
nephropathy
THE MOLECULAR AND CELLULAR mechanisms responsible for di-
abetic nephropathy remain incompletely resolved. While stud-
ies indicate involvement of hyperglycemia via the stimulation
of growth factor-induced cellular hypertrophy (48), increased
production of extracellular matrix (ECM) protein (2), and
decreased production of matrix-degrading proteinases (20), the
underlying signal transduction mechanisms mediating these
processes have been less well explored.
Numerous studies reveal protein kinase C (PKC) activation
in diabetic glomeruli (5) and in mesangial cells cultured under
high-glucose conditions (42). PKC propagates the physiologi-
cal responses of receptor-ligand interactions via an array of
downstream signals, such as mitogen-activated protein kinases
(MAPKs). p38 MAPK, a member of the MAPK family, is
known to be activated in response to stress signals, such as
proinflammatory cytokines (28, 34), ultraviolet irradiation
(34), osmolality changes (28, 34), and oxidative stress (4, 28),
leading to apoptosis (43), prostanoid production (22), and other
cellular dysfunctions (8). Since hyperosmolality and oxidant
stress characterize the diabetic state, p38 MAPK has been
posited to mediate the pathogenesis of diabetic complications.
Increased p38 MAPK activity has been observed in the aorta
and the glomeruli of diabetic rats and in vascular smooth
muscle cells and mesangial cells cultured under high-glucose
conditions, along with increased ECM synthesis (9, 13, 14, 30).
Oxidant stress, a strong activator of the p38 MAPK pathway,
was a proximate event in high-glucose-induced mesangial cell
apoptosis (12). In addition, methylglyoxal, a potent precursor
of advanced glycation end products, induced apoptosis in
cultured mesangial cells via the p38 MAPK pathway (25).
These in vitro findings suggest that the p38 MAPK pathway
may be involved in the pathogenesis of ECM accumulation and
mesangial cell apoptosis under diabetic conditions. However,
the direct relationship between apoptosis and the p38 MAPK
pathway has never been documented in diabetic glomeruli and
in mesangial cells exposed to high glucose. In addition, the
consequences of the inhibition of the p38 MAPK pathway have
not been well elucidated in diabetic glomeruli.
In this study, we examined the effect of FR167653 on the
p38 MAPK pathway in isolated glomeruli from diabetic rats
and in mesangial cells cultured under high-glucose conditions.
In addition to p38 MAPK, we also studied the effect of
FR167653 on the following: 1) cAMP-responsive element
(CRE) binding protein (CREB), a transcription factor that is
known to be under control of p38 MAPK; 2) fibronectin, a key
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ECM protein produced by mesangial cells; and 3) apoptosis-
related molecules, such as Bax, Bcl-2, and caspase-3.
METHODS
Animals. All animal studies were conducted under an approved
protocol. Thirty-two male Sprague-Dawley rats, weighing 250–280 g
(8–9 wk old), were injected either with diluent [n  16, control (C)]
or with 65 mg/kg streptozotocin intraperitoneally [n 16, diabetes (DM)].
Eight rats from each group were treated with 2 mg kg1 day1 of
FR167653 (kindly donated from Astellas Pharma, Tokyo, Japan)
(diluted in 0.9% saline) by intramuscular injection (CFR, DMFR)
for 3 mo, while C and DM rats were injected with similar volume of
0.9% saline. Since the previous study has shown that glomerular p38
MAPK activity was increased for the first 3 mo after DM induction by
streptozotocin (15), we decided to administer FR167653 for 3 mo in
this study. In addition, the dose of FR167653 was determined based
on the previous study by Lu et al. (26). Rats were housed in a
temperature-controlled room and were given free access to water and
standard laboratory chow during the 3-mo study period.
Body weights were checked monthly, and kidney weights were
measured at the time of death. Systolic blood pressure was measured
by tail-cuff plethysmography at 3 mo. Serum glucose and 24-h urinary
albumin were also measured at the time of death. Blood glucose was
measured by glucometer, and 24-h urinary albumin excretion was
determined by ELISA (Nephrat II, Exocell, Philadelphia, PA).
Glomerular isolation. Glomeruli were isolated by sieving. Purity of
the glomerular preparation was greater than 98%, as determined by
light microscopy.
Mesangial cell culture. Isolated glomeruli from male Sprague-
Dawley rats were incubated in collagenase and trypsin-EDTA (Gibco
Laboratories, Bethesda, MD), as described previously (1). Mesangial
cells were maintained in RPMI 1640 media (Sigma Chemical, St.
Louis, MO), supplemented with L-glutamine, 7 mM HEPES, and 10%
fetal bovine serum (Gibco Laboratories), and incubated at 37°C in
humidified 5% CO2 in air.
To determine the effect of FR167653 on high-glucose-induced
fibronectin and apoptosis-related molecule expression, rat mesangial
cells were serum restricted for 24 h, and the medium was changed to
serum-free RPMI medium containing normal glucose (5.6 mM; NG),
high glucose (30 mM; HG), or NG  mannitol (24.4 mM) with or
without 106 M FR167653. The concentrations of FR167653 used in
this study were determined based on preliminary experiments. Cells
were harvested for either RNA or protein at 24 h after the media
change.
Total RNA extraction and reverse transcription. Total RNA was
extracted from isolated glomeruli as previously described (15), and
first-strand cDNA was made by using a Boehringer Mannheim cDNA
synthesis kit (Boehringer Mannheim, Mannheim, Germany). Two
micrograms of total RNA extracted from sieved glomeruli were
reverse transcribed using 10 M random hexanucleotide primer, 1
mM dNTP, 8 mM MgCl2, 30 mM KCl, 50 mM Tris HCl, pH 8.5, 0.2
mM dithiothreithol, 25 units RNase inhibitor, and 40 units avian
myeloblastosis virus reverse transcriptase. The mixture was incubated
at 30°C for 10 min and 42°C for 1 h, followed by inactivation of the
enzyme at 99°C for 5 min. Cellular RNA from each plate was
similarly reverse transcribed.
Real-time polymerase chain reaction. The primers used for fi-
bronectin and GAPDH amplification were as follows: fibronectin
sense, 5-TGACAACTGCCGTAGACCTGG-3, antisense 5-TACT-
GGTTGTAGGTGTGGCCG-3; and GAPDH sense 5-CGAGAAT-
GGGAAGCTTGTCATC-3, antisense 5-CGGCCTCACCCCATTTG-
3. cDNAs synthesized from 20 ng RNA of glomeruli or cells were used
per reaction for amplification.
Using the ABI PRISM 7700 Sequence Detection System (Applied
Biosystems, Foster City, CA), polymerase chain reaction (PCR) was
performed with a total volume of 20 l in each well, containing 10 l
of SYBR Green PCR Master Mix (Applied Biosystems), 5 l of
cDNA, and 5 pmol of sense and antisense primers. Primer concen-
trations were determined by preliminary experiments that analyzed
the optimal concentrations of each primer. Each sample was run in
triplicate in separate tubes to permit quantification of the fibronectin
gene expression normalized to the GAPDH. The PCR conditions used
were as follows: for GAPDH, 35 cycles of denaturation at 94.5°C for
30 s, annealing at 58°C for 30 s, and extension at 72°C for 1 min; and
for fibronectin, 38 cycles of denaturation at 94.5°C for 30 s, annealing
at 62°C for 30 s, and extension at 72°C for 30 s. An initial heating at
95°C for 9 min and a final extension at 72°C for 7 min were performed
for all PCR reactions. After real-time PCR, the temperature was
increased from 60 to 95°C at a rate of 2°C/min to construct a melting
curve. A control without cDNA was run in parallel with each assay.
The cDNA content of each specimen was determined using a com-
parative threshold cycle (CT) method with 2 CT. The results were
given as relative expression normalized to the GAPDH gene and
expressed in arbitrary units. Signals from C glomeruli and NG cells
were assigned a relative value of 1.0. In pilot experiments, PCR
products run on agarose gels revealed a single band.
Western blot analysis. Sieved glomeruli and cells harvested from
plates were lysed in sodium dodecyl sulfate (SDS) sample buffer [2%
SDS, 10 mM Tris HCl, pH 6.8, 10% (vol/vol) glycerol], treated with
Laemmli sample buffer, heated at 100°C for 5 min, and electropho-
resed in an 8% acrylamide denaturing SDS-polyacrylamide gel. Pro-
teins were then transferred to a Hybond-ECL membrane using a
Hoeffer semidry blotting apparatus (Hoeffer Instruments, San Fran-
cisco, CA), and the membrane was then incubated in blocking buffer
A (1  PBS, 0.1% Tween 20, and 8% nonfat milk) for 1 h at room
temperature, followed by an overnight incubation at 4°C in a 1:1,000
dilution of polyclonal antibodies to p38 MAPK, phospho-specific p38
MAPK, CREB, phospho-specific CREB, extracellular signal-regu-
lated kinase-1/2 (ERK1/2), phospho-specific ERK1/2, c-Jun NH2-
amino terminal kinase (JNK), phospho-specific JNK, PKC (New
England Biolaboratories, Beverly, MA), extracellular domain of fi-
bronectin, Bax, Bcl-2 (Santa Cruz Biotechnology, Santa Cruz, CA),
active fragments of caspase-3, total caspase-3 (Cell Signaling, Bev-
erly, MA), or 	-actin (Santa Cruz Biotechnology). The membrane was
then washed once for 15 min and twice for 5 min in 1  PBS with
0.1% Tween 20. Next, the membrane was incubated in buffer A
containing a 1:1,000 dilution of horseradish peroxidase-linked goat
anti-rabbit IgG (Amersham Life Science, Arlington Heights, IL). The
washes were repeated, and the membrane was developed with a
chemiluminescent agent (ECL; Amersham Life Science), and the
band densities were measured using TINA image software (Raytest,
Straubenhardt, Germany).
Terminal deoxynucleotidyl transferase dUTP-mediated nick-end
labeling assay and Hoechst 33342 staining. In addition to the changes
in the expression of apoptosis-related molecules, apoptosis was also
identified within glomeruli by terminal deoxynucleotidyl transferase
dUTP-mediated nick-end labeling (TUNEL) using commercially
available kit (Chemicon International, Temecula, CA) and in cultured
mesangial cells seeded on coverslips by Hoechst 33342 (Molecular
Probes, Eugene, OR) staining. Apoptosis was defined as TUNEL-
positive cells within glomeruli and the presence of nuclear conden-
sation on Hoechst staining. TUNEL-positive glomerular cells in
formalin-fixed renal tissue and the percentage of mesangial cells with
nuclear condensation were determined by examining at least 30
glomeruli and 300 cells per condition, respectively, at 400 magni-
fication.
Immunohistochemistry. Slices of kidney for immunohistochemical
staining were snap-frozen in optimal cutting temperature solution, and
4-m sections of tissues were utilized. Slides were fixed in acetone for
10 min at 4°C, air dried for 10 min at room temperature, and blocked
with 10% donkey serum for 20 min at room temperature. For fi-
bronectin staining, the primary polyclonal antibody to the extracellu-
lar domain of fibronectin (Santa Cruz Biotechnology) was diluted in
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1:100 with 2% casein in BSA and was applied for overnight incuba-
tion at room temperature. After washing, a secondary goat anti-rabbit
antibody was added for 20 min, and the slides were then washed and
incubated with a tertiary rabbit-peroxidase-antiperoxidase complex
for 20 min. 3,3-Diaminobenzidine was added for 2 min, and the
slides were counterstained with hematoxylin. A semiquantitative
score for measuring the intensity of fibronectin staining within glo-
meruli was determined by examining 30 glomeruli in each section and
by digital image analysis (MetaMorph version 4.6r5, Universal Im-
aging, Downingtown, PA), as previously described (16).
Statistical analysis. All values are expressed as means 
 SE.
Statistical analysis was performed using the statistical package SPSS
for Windows version 11.0 (SPSS, Chicago, IL). Results were ana-
lyzed using the Kruskal-Wallis nonparametric test for multiple com-
parisons. Significant differences by the Kruskal-Wallis test were
further confirmed by the Mann-Whitney U-test. P values 0.05 were
considered to be statistically significant.
RESULTS
Animal data. All animals gained weight over the 3-mo
experimental period, but weight gain was highest in C rats
(P  0.01). The ratio of kidney weight to body weight in DM
rats (1.46 
 0.09%) was significantly higher than that in C
(0.57 
 0.05%), CFR (0.53 
 0.06) (P  0.01), and
DMFR rats (0.93 
 0.07%) (P  0.05). The mean blood
glucose levels of C, CFR, DM, and DMFR rats were
109.9 
 6.5, 112.5 
 8.3, 487.5 
 14.4, and 479.0 
 13.2
mg/dl, respectively (P  0.01). Compared with the C group
(0.35 
 0.06 mg/day), 24-h urinary albumin excretion was
significantly higher in the DM group (1.87 
 0.26 mg/day,
P  0.05), and FR167653 treatment significantly reduced
albuminuria in DM rats (0.77 
 0.16 mg/day, P  0.05).
p38 MAPK activity and protein expression. Figure 1 shows
a representative Western blot of equal amounts of protein from
the lysates of sieved glomeruli from the four groups. The blot
was first probed with an antibody to phospho-specific p38
MAPK and then stripped and probed with an antibody that
recognizes total p38 MAPK. Phospho-specific (activated) p38
MAPK levels were significantly greater in the DM compared
with C and CFR glomeruli (P  0.05). FR167653 treatment
nearly normalized the increase in glomerular p38 MAPK
activity in DM rats (P  0.05). In contrast, no significant
differences were found in total p38 MAPK expression among
the four groups.
The effects of FR167653 on p38 MAPK activity and protein
expression in HG-stimulated mesangial cells are shown in
Fig. 2. HG activated the p38 MAPK pathway in cultured
mesangial cells, and this HG-induced p38 MAPK activity was
ameliorated by 79% with 106 M FR167653 treatment (P 
0.01). In contrast, FR167653 had no effect on total p38 MAPK
protein expression in cultured mesangial cells.
On the other hand, we tested whether the inhibitory effect of
FR167653 was specific on the p38 MAPK pathway. As seen in
Fig. 3, the increases in ERK1/2 and JNK activities and PKC
protein expression in HG-stimulated mesangial cells were not
affected by FR167653 treatment.
CREB activity and protein expression. To determine whether
activation of the p38 MAPK pathway could induce parallel
increases in the activity of a p38 MAPK target transcription
factor, we examined the activity and protein expression of
CREB. The representative blot in Fig. 1 shows that phospho-
specific (activated) CREB expression was significantly higher
in DM relative to C and CFR glomeruli (P  0.01). Similar
to p38 MAPK activity, FR167653 treatment ameliorated the
increase in glomerular CREB activity in DM rats (P  0.05).
In contrast, there were no significant differences in total CREB
levels among the four groups.
The effects of FR167653 on CREB activity and protein
expression in HG-stimulated mesangial cells were similar
to those on p38 MAPK activity and protein expression. HG
Fig. 1. Representative Western blot of glomerular
phospho-specific and total p38 mitogen-activated
protein kinase (MAPK) and cAMP-responsive ele-
ment binding protein (CREB) in control (C), C 
FR167653-treated (FR), diabetes (DM), and DMFR
groups (representative of four blots). Phospho-spe-
cific p38 MAPK-to-total p38 MAPK and phospho-
specific CREB-to-total CREB ratios were signifi-
cantly greater in DM compared with C (1.8-fold and
2.2-fold, respectively) and CFR glomeruli, and
FR167653 treatment nearly normalized the in-
creases in glomerular p38 MAPK and CREB activ-
ities in the DM group. In contrast, there were no
differences in total p38 MAPK, total CREB, and
	-actin protein expression among the four groups.
*P  0.05 vs. other groups; #P  0.01 vs. C and
CFR groups; †P  0.05 vs. DM group.
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induced CREB activation in mesangial cells, and this HG-
induced CREB activity was ameliorated by 87% with 106
M FR167653 treatment (P  0.01). In contrast, FR167653
had no effect on total CREB levels in cultured mesangial
cells (Fig. 2).
Fibronectin mRNA and protein expression. To correlate
our observations to evolving diabetic nephropathy, we ex-
amined the mRNA and protein expression of fibronectin, a
key ECM protein of mesangial cells. The glomerular fi-
bronectin mRNA expression was significantly increased in
DM compared with C and CFR rats (P  0.05). On the
other hand, there was no difference in GAPDH mRNA
expression among the four groups (data not shown). The
fibronectin-to-GAPDH mRNA ratio and fibronectin protein
expression were 2.1- and 1.9-fold higher, respectively, in
DM relative to C glomeruli (P  0.05), and these incre-
ments were inhibited by 89 and 79%, respectively, with
FR167653 treatment (P  0.05) (Fig. 4).
HG also induced fibronectin mRNA and protein expression
in cultured mesangial cells. The cellular fibronectin mRNA
expression was significantly increased in HG-stimulated mes-
angial cells compared with NG cells (P  0.01). On the other
hand, there was no difference in GAPDH mRNA expression
among the groups (data not shown). The fibronectin-to-
GAPDH mRNA ratio and fibronectin protein expression were
2.3- (P 0.01) and 1.7-fold higher (P 0.05), respectively, in
mesangial cells exposed to HG, and FR167653 treatment
ameliorated these increments in fibronectin expression in HG
cells (Fig. 5).
Bax, Bcl-2, and active fragments of caspase-3 protein
expression. Bcl-2 protein expression was significantly de-
creased, while active fragments of caspase-3 protein expres-
sion were significantly increased in DM glomeruli and
HG-stimulated mesangial cells (P  0.01), and these
changes were inhibited by FR167653, both in vivo and
in vitro. On the other hand, Bax protein expression was
significantly increased in DM compared with C glomeruli,
and FR167653 treatment abrogated this increment in DM
glomeruli. An increase in Bax protein expression was also
observed in HG-stimulated mesangial cells but did not reach
statistical significance (Figs. 6 and 7).
TUNEL assay and Hoechst 33342 staining. Apoptotic cells
assessed by TUNEL assay and Hoechst 33342 staining were
significantly increased in DM glomeruli (P  0.01) and HG-
stimulated mesangial cells (P  0.05) compared with C glo-
meruli and NG cells, respectively, and these increases in apop-
totic cells were ameliorated by FR167653, both in vivo and in vitro
(P  0.05) (Fig. 8).
Immunohistochemistry. Immunohistochemical staining for glo-
merular fibronectin confirmed the Western blot findings.
Glomerular fibronectin staining within mesangial regions
was significantly stronger in DM compared with C rats, and
FR167653 treatment inhibited the increase in glomerular
fibronectin accumulation in DM rats (Fig. 9). The mean
semiquantitative staining scores for glomerular fibronectin
were significantly higher in DM (86.3 
 11.1) compared
with C rats (28.5 
 5.8) (P  0.05), and FR167653
treatment attenuated this increment in DM glomeruli
(41.1 
 6.9) (P  0.05).
DISCUSSION
Diabetic milieu is known to activate the p38 MAPK pathway
in various cells and organs (9, 13, 14, 16, 30, 44); however, the
consequences of inhibiting p38 MAPK activation under dia-
betic conditions have not been well explored in diabetic ne-
phropathy. In this study, we demonstrate for the first time that
fibronectin expression and apoptosis in diabetic glomeruli and
Fig. 2. Representative Western blot of phospho-
specific and total p38 MAPK and CREB in cultured
mesangial cells (representative of four blots). High
glucose (HG) significantly induced phospho-spe-
cific p38 MAPK and CREB levels in cultured mes-
angial cells, and these increments in p38 MAPK and
CREB activities were ameliorated by FR167653
treatment. In contrast, FR167653 and mannitol (M)
had no effects on total p38 MAPK, total CREB, and
	-actin protein expression in cultured mesangial
cells. NG, normal glucose. *P  0.01 vs. other
groups.
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HG-stimulated mesangial cells were ameliorated with the ad-
ministration of FR167653, a p38 MAPK inhibitor.
p38 MAPK is a member of the MAPK family and is known
as a “stress-activated kinase,” along with JNK (7, 24, 36).
Biochemical studies have demonstrated that the p38 MAPK
signaling pathway activates various transcription factors, in-
cluding CREB (10). CREB is a member of a transcription
factor family that converts rapid and transient signals into
long-term changes in gene expression by binding to the CRE.
Since the fibronectin promoter contains a CRE (3), activated
CREB can bind the CRE portion of the fibronectin gene,
leading to fibronectin mRNA expression. Kreisberg et al. (23)
have demonstrated that activation of PKC by HG plus trans-
forming growth factor-	 or phorbol myristate acetate induced
phosphorylation of CREB, resulting in the stimulation of
fibronectin transcription in mesangial cells in vitro. These
studies suggest that activation of p38 MAPK in diabetic glo-
meruli and in HG-stimulated mesangial cells is involved in
fibronectin accumulation. We now report that treatment with a
p38 MAPK inhibitor in vivo and in vitro ameliorated p38
MAPK phosphorylation and that the increase in fibronectin
expression was subsequently inhibited.
FR167653 was originally developed as a dual inhibitor of
interleukin-1 and tumor necrosis factor (TNF)- production
(47). Previous studies have demonstrated that FR167653 ame-
liorated ischemia-reperfusion injury in the lung, pancreas, and
kidney, possibly by inhibition of proinflammatory cytokine
production (18, 31, 46). In rats with nephrotoxic serum nephri-
tis, an animal model of human crescentic glomerulonephritis,
urinary excretion and renal expression of monocyte chemoat-
tractant protein-1 were decreased by FR167653 (41). FR167653
also reduced the renal expression of monocyte chemoattractant
protein-1 and TNF- in an animal model of human lupus
erythematosus, resulting in prolonged survival and attenuated
renal pathological changes (11). Since glomerular infiltration
of leukocytes has a major role in the pathogenesis of nephro-
toxic serum nephritis and lupus nephritis, the effects of
FR167653 seem to be mediated by its anti-inflammatory ac-
tions, i.e., inhibition of cytokine production by monocytes and
macrophages. Very recently, Moriwaki et al. (29) have dem-
onstrated that urinary albumin excretion is decreased in
FR167653-treated diabetic rats, along with modest decrease
in the urinary excretion of TNF-, suggesting an important
role of TNF- in the pathogenesis of diabetic nephropathy.
In that study, however, the pathological changes, such as
ECM accumulation or inflammatory cell infiltration, were
not investigated. Since cellular infiltration within glomeruli
is not extensive in 3-mo diabetic rat compared with tubulo-
interstitial area, we did not evaluate the effect of FR167653
on the synthesis of proinflammatory cytokines in diabetic
glomeruli.
Fig. 3. Representative Western blot of phospho-specific and total extracellular signal-regulated kinase (ERK)-1/2, c-Jun NH2-amino terminal kinase (JNK), and
total protein kinase C (PKC) in cultured mesangial cells (representative of four blots). FR167653 treatment did not affect the increases in ERK1/2 and JNK
activities and total PKC protein expression in HG-stimulated mesangial cells. *P  0.05 vs. NG, NGM, and NGFR groups.
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Besides the anti-inflammatory effects, recent studies have
revealed that FR167653 is a selective p38 MAPK inhibitor
and competes with ATP at the ATP-binding site of p38
MAPK (39). In addition, a previous study demonstrated that
FR167653 did not affect the activities of other protein
kinases, such as ERK1/2, JNK, PKC, or PKA (39). In this
study, we also observed that the increases in ERK1/2 and
JNK activities and PKC protein expression in HG-stimu-
lated mesangial cells were not affected by FR167653 treat-
ment, suggesting that the inhibitor effect of FR167653 was
specific on the p38 MAPK pathway in cultured mesangial
cells under diabetic conditions. In contrast to SB203580,
another p38 MAPK inhibitor, it is known that FR167653 has
no effect on cyclooxygenase-1 or -2 activity (39). By inhib-
iting the p38 MAPK pathway, renal NAD(P)H oxidase
expression and superoxide formation were suppressed, and
renal damage was ameliorated by FR167653 treatment in
Dahl salt-sensitive rats with heart failure, suggesting that the
renoprotective effect of FR167653 was associated with the
inhibition of oxidative stress (40). In addition, the study by
Koshikawa et al. (21) demonstrated that p38 MAPK activa-
tion played an important role in podocyte injury in protein-
uric glomerulopathies, including rat puromycin amino-
nucleoside nephropathy and mouse adriamycin nephropa-
thy. Taken together, it seems that FR167653 can exert
renoprotective effects by inhibiting the p38 MAPK pathway
per se in various kidney diseases, even in which inflamma-
tory cell infiltration is minimal or insignificant.
Apoptosis, usually known as programmed cell death,
removes damaged or unwanted cells and has been impli-
Fig. 5. A: fibronectin mRNA expression assessed by real-time PCR in cultured
mesangial cells (N  5). HG significantly increased fibronectin-to-GAPDH
mRNA ratio in cultured mesangial cells, and this increment in fibronectin
mRNA expression was inhibited by FR167653 treatment. In contrast,
FR167653 and M had no effects on fibronectin mRNA expression in cultured
mesangial cells. *P  0.01 vs. NG, NGM, and NGFR groups; #P  0.05
vs. HG group. B: representative Western blot of cellular fibronectin in cultured
mesangial cells (representative of four blots). Fibronectin protein expression
was significantly increased in HG-stimulated mesangial cells compared with NG
cells, and FR167653 treatment ameliorated this increment in fibronectin protein
expression in HG cells. †P  0.05 vs. other groups.
Fig. 4. A: fibronectin mRNA expression assessed by real-time PCR in C,
CFR, DM, and DMFR glomeruli. The glomerular fibronectin-to-GAPDH
mRNA ratio was 2.1-fold higher in DM compared with C rats, and this
increment was inhibited by 89% with FR167653 treatment. On the other hand,
FR167653 treatment had no effect on fibronectin mRNA expression in C rats.
B: representative Western blot of glomerular fibronectin in C, CFR, DM, and
DMFR groups (representative of four blots). Fibronectin protein expression
was significantly increased in DM compared with C and CFR glomeruli, and
FR167653 treatment ameliorated this increment in glomerular fibronectin
protein expression in the DM group. *P  0.05 vs. other groups.
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cated in the pathogenesis of numerous diseases, such as
malignancy, lupus erythematosus, and Alzheimer’s disease
(35). In addition, it has been documented in the course of
various renal diseases, including diabetic nephropathy (6,
19, 38). Cell death by apoptosis is surmised to be involved
in the process of mesangial cell loss in the late stage of
diabetic nephropathy, suggesting that apoptosis may be a
homeostatic mechanism regulating the glomerular cell pop-
ulation. Previous reports have demonstrated that high-glu-
cose stimulated caspase-3 cleavage and DNA fragmentation
in cultured mesangial cells (17, 27). Apoptosis of mesangial
cells was also induced by hyperglycemia-related factors,
methylglyoxal (25), advanced glycation end products (45),
and transforming growth factor-	 (33). On the other hand,
numerous studies have investigated the signal transduction
pathways mediating apoptosis in mesangial cells, and, as a
Fig. 6. Bax, Bcl-2, and cleaved caspase-3 pro-
tein expression assessed by Western blot in C,
CFR, DM, and DMFR glomeruli (represen-
tative of four blots). Not only Bax protein, but
also cleaved caspase-3 protein expression was
significantly increased in DM glomeruli, and
these increments were inhibited by FR167653
treatment. In contrast, Bcl-2 protein expression
was significantly decreased in DM glomeruli,
and FR167653 treatment ameliorated this dec-
rement in Bcl-2 protein expression. *P  0.01
vs. other groups.
Fig. 7. Bax, Bcl-2, and cleaved caspase-3 protein
expression assessed by Western blot in cultured
mesangial cells (representative of four blots). Bcl-2
protein expression was significantly decreased,
while cleaved caspase-3 protein expression was sig-
nificantly increased in HG-stimulated mesangial cells,
and these changes were inhibited by FR167653 treat-
ment. On the other hand, Bax protein expression
was increased in HG-stimulated mesangial cells, but
did not reach statistical significance. *P  0.01 vs.
other groups; #P  0.01 vs. NG, NGM, and
NGFR groups; †P  0.05 vs. HG group.
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result, the p38 MAPK pathway has been revealed to mediate
mesangial cell apoptosis induced by several factors, includ-
ing methylglyoxal (25), adrenomedullin (32), and homocys-
teine (37). However, the direct relationship between apop-
tosis and the p38 MAPK pathway has never been docu-
mented in diabetic glomeruli and in mesangial cells exposed
to high glucose. Based on the results that treatment with a p38
MAPK inhibitor ameliorated apoptosis in diabetic glomeruli and
Fig. 8. Apoptosis assessed by terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling assay (A) and Hoechst 33342 staining (B). There was a
significant increase in apoptotic cells (arrow heads) in DM glomeruli (large arrow heads, mesangial cells; small arrow heads, podocytes) and HG-stimulated
mesangial cells compared with C glomeruli and NG cells, respectively, and this increase in apoptotic cells was ameliorated by FR167653, both in vivo and
in vitro (400). *P  0.01 vs. C and CFR groups; #P  0.05 vs. DM group; †P  0.05 vs. other groups.
Fig. 9. Immunohistochemical staining for fibronectin in
C, CFR, DM, and DMFR groups. There was a signif-
icant increase in glomerular fibronectin protein expression
in DM compared with C and CFR rats, and this increase
was ameliorated by FR167653 treatment (400).
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high-glucose stimulated mesangial cells, the present study pro-
vides strong evidence that activation of p38 MAPK is closely
linked to mesangial cell apoptosis under diabetic conditions.
In summary, FR167653 inhibited p38 MAPK activation and
ameliorated fibronectin expression and apoptosis in diabetic
glomeruli and in mesangial cells cultured under high-glucose
conditions. These findings suggest that p38 MAPK could be a
potential target for preventing nephropathy in diabetes.
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